Immunohistochemistry (IHC) Market Report 2025

The immunohistochemistry (IHC) market size has grown strongly in recent years. It will grow from $2.58 billion in 2024 to $2.78 billion in 2025 at a compound annual growth rate (CAGR) of 8%. The growth in the historic period can be attributed to clinical adoption, industry standardization, expansion in cancer research, automation in laboratories, clinical diagnostics advancements.

The immunohistochemistry (IHC) market size is expected to see rapid growth in the next few years. It will grow to $4.13 billion in 2029 at a compound annual growth rate (CAGR) of 10.4%. The growth in the forecast period can be attributed to market entry of new players, demand in drug development, biomedical research integration, diagnostic applications, automation and digitalization. Major trends in the forecast period include multiplex IHC techniques, digital pathology integration, enhanced antibody specificity, automation and standardization, application in biomarker discovery.

The immunohistochemistry (IHC) market is anticipated to witness growth due to the increasing prevalence of chronic diseases. Chronic diseases, lasting for extended periods and typically manageable but not curable, include conditions such as cancer and cardiovascular disorders. Immunohistochemistry is crucial in diagnosing these diseases, offering advantages such as specificity, sensitivity to detect specific antigens, and rapid results. In 2022, the Centers for Disease Control and Prevention reported that approximately 37.3 million people in the United States, accounting for 11.3% of the population, have diabetes, emphasizing the role of immunohistochemistry in addressing the rising burden of chronic diseases.

The growth of the immunohistochemistry (IHC) market is further driven by the increasing demand for personalized medicines. Personalized medicine tailors medical decisions and interventions based on individual patients' unique genetic, environmental, and lifestyle characteristics. Immunohistochemistry plays a significant role in this context, detecting specific protein markers crucial for accurate tumor classification and diagnosis. The Personalized Medicine Coalition projected that over 75,000 genetic testing products and 300 personalized medicines will be available for various diseases, reinforcing the pivotal role of immunohistochemistry in advancing personalized medicine.

Major players in the immunohistochemistry (IHC) market are concentrating on improving diagnostic accuracy through innovative technologies and high-quality reagents to enhance tissue analysis effectiveness in various clinical and research contexts. The Neoflex multiomics mass spectrometry imaging (MSI) system is a cutting-edge imaging platform tailored for precise tissue analysis, enabling researchers to progress from discovery to clinical applications using high-resolution mass spectrometry techniques, especially for spatially mapping biomolecules in tissues. For example, in June 2024, Bruker Corporation, a US-based company that develops and manufactures scientific instruments along with analytical and diagnostic solutions, introduced its matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF/TOF) Neoflex Imaging Profiler for mass spectrometry-based tissue imaging. The Neoflex MSI system addresses the demand for advancing from discovery imaging to clinical tissue research. It incorporates Bruker's 10-kHz smartbeam 3D laser, improved imaging detectors, and supports OME-TIFF file output with SCiLS Scope software.

Leading companies in the immunohistochemistry (IHC) market are prioritizing technological advancements, such as automated staining systems, to boost diagnostic accuracy and efficiency for pathologists, ultimately improving patient outcomes. The Tissue-Tek Genie represents an innovative, fully automated staining system for immunohistochemistry (IHC) and in situ hybridization (ISH), designed to deliver rapid, high-quality, and standardized results to enhance diagnostic precision in histopathology. For instance, in September 2022, Sakura Finetek, a US-based medical equipment company, launched its latest solution, Tissue-Tek Genie, an advanced staining system focused on providing optimal scoring antibodies for the best possible results for pathologists and their patients. The Tissue-Tek Genie Advanced Staining System is the first fully automated, true random access stainer for immunohistochemistry (IHC) and in situ hybridization (ISH).

In November 2022, Leica Biosystems, a Germany-based medical devices firm, acquired Cell IDx, Inc. for an undisclosed sum. This acquisition aims to enhance Leica Biosystems' multiplex immunohistochemistry (IHC) capabilities and improve cancer diagnostics by integrating its UltraPlex technology for advanced biomarker detection and tissue-based diagnostics. Cell IDx is a US-based biotechnology company specializing in multiplexed tissue profiling.

Major companies operating in the immunohistochemistry (IHC) market include Thermo Fisher Scientific Inc., F. Hoffmann-La Roche AG, The Merck Group, Danaher Corporation, PerkinElmer Inc., Bio-Rad Laboratories Inc., Cell Signaling Technology Inc., Bio SB Inc., Agilent Technologies Inc., Abcam plc, Becton Dickinson and Company, Takara Bio Inc., Biocare Medical LLC, Bio-Genex Laboratories, Diagnostic BioSystems Inc., BioVision Inc., PHC Holdings Corporation, Abbott Laboratories, Leica Biosystems, Vector Laboratories, Indivumed GmbH, Qritive, Ionpath Inc., Reveal Biosciences, Akrivis Technologies Private Limited, LifeSpan BioSciences Inc., Enzo Life Sciences Inc., Epitomics Inc., GenScript Biotech, Histologix Ltd., NeoGenomics Laboratories Inc.

North America was the largest region in the immunohistochemistry (IHC) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the immunohistochemistry (IHC) market report during the forecast period. The regions covered in the immunohistochemistry (ihc) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the immunohistochemistry (ihc) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Immunohistochemistry (IHC) is a diagnostic technique that utilizes the interaction between antibodies and antigens to identify specific proteins and antigens within tissue sections. This interaction is visualized through chromogenic detection using enzyme-substrate or fluorescent detection using fluorescent dyes.

The main products associated with immunohistochemistry (IHC) include antibodies, equipment, reagents, and kits. Antibodies are proteins produced by the immune system to neutralize harmful antigens, and in the context of IHC, they are employed to detect the specific location of proteins or antigens for diagnostic purposes. The applications of IHC span diagnostics, drug testing, and other related areas, with end-users including hospitals, diagnostic laboratories, research institutes, and others.

The immunohistochemistry (IHC) market research report is one of a series of new reports that provides immunohistochemistry (IHC) market statistics, including immunohistochemistry (IHC) industry global market size, regional shares, competitors with a immunohistochemistry (IHC) market share, detailed immunohistochemistry (IHC) market segments, market trends and opportunities, and any further data you may need to thrive in the immunohistochemistry (IHC) industry. This immunohistochemistry (IHC) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The immunohistochemistry (IHC) market consists of sales of primary antibodies, slide staining system, tissue microarrays, tissue processing systems, slide scanners secondary antibodies, histological stains, blocking sera and reagents, chromogenic substrates, fixation reagents and stabilizers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.